| 疏血通注射液辅助治疗94例慢性肺心病急性期患者的临床疗效 |
| 投稿时间：2014-07-07 修订日期：2014-12-16 点此下载全文 |
| 引用本文：郑佳,王树全.疏血通注射液辅助治疗94例慢性肺心病急性期患者的临床疗效[J].药学实践杂志,2015,33(3):269~271 |
| 摘要点击次数: 1094 |
| 全文下载次数: 369 |
|
|
| 中文摘要:目的 观察慢性肺心病患者在基础治疗前提下,给予疏血通注射液改善患者心肺功能的效果。方法 对照组给予持续低流量吸氧、敏感抗生素控制感染、止咳化痰、解痉平喘等治疗。观察组在此基础上给予疏血通注射液6 ml,每天1次,14 d为1个疗程。结果 观察组总有效率为93.75%,对照组总有效率为67.39%,观察组疗效经卡方检验(χ2=11.36,P=0.00)优于对照组(P<0.05)。观察组血液流变学各项指标均较治疗前明显改善(P<0.05),且优于对照组(P<0.01)。两组肺功能相关指标改善情况比较,差异均有统计学意义(P<0.01)。结论 疏血通注射液辅助治疗能有效地改善微循环、减轻炎症反应,改善患者预后,在基础治疗上加用疏血通注射液治疗慢性肺心病可以明显提高疗效,值得临床推广使用。 |
| 中文关键词:慢性肺心病 疏血通注射液 血液流变学 肺功能 |
| |
| Clinical efficacy of Shuxuetong injection in the treatment of 94 acute stage patients of chronic pulmonary heart disease |
|
|
| Abstract:Objective To observe the effect of Shuxuetong injection in the improvement of heart and lung function on chronic pulmonary heart disease patients with basic treatment. Methods The control group was given low flow oxygen, sensitive antibiotics for infection control, and other treatments such as cough relief, sputum reduction, and antispasmodic treatment. Treatment group was given 6 ml Shuxuetong injection once a day for 14 days as 1 treatment period. Results The total effective rate of treatment group was 93.75%, while that of total control group was 67.39% (P<0.05) from Chi square test(χ2=11.36, P=0.00). All indexes of blood rheology of treatment group significantly improved compared with self control at an earlier time (P<0.05) and control group (P<0.01). Improvement of the index of pulmonary function between two groups was significant difference(P<0.01). Conclusion Shuxuetong injection as an adjuvant treatment would improve microcirculation, reduce inflammation, and improve patient outcomes. Therapy combined with Shuxuetong injection in the treatment of chronic pulmonary heart disease could significantly improve the efficacy, therefore, which would be worth of clinical use. |
| keywords:chronic pulmonary heart disease Shuxuetong injection blood rheology lung function |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
